CA2438339C - Use of buprenorphine for treatment of urinary incontinence - Google Patents

Use of buprenorphine for treatment of urinary incontinence Download PDF

Info

Publication number
CA2438339C
CA2438339C CA2438339A CA2438339A CA2438339C CA 2438339 C CA2438339 C CA 2438339C CA 2438339 A CA2438339 A CA 2438339A CA 2438339 A CA2438339 A CA 2438339A CA 2438339 C CA2438339 C CA 2438339C
Authority
CA
Canada
Prior art keywords
buprenorphine
amount
body weight
pharmaceutical composition
daily administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2438339A
Other languages
English (en)
French (fr)
Other versions
CA2438339A1 (en
Inventor
Johannes Bartholomaeus
Thomas Christoph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001107828 external-priority patent/DE10107828A1/de
Priority claimed from DE20115429U external-priority patent/DE20115429U1/de
Priority claimed from DE2001162704 external-priority patent/DE10162704A1/de
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CA2438339A1 publication Critical patent/CA2438339A1/en
Application granted granted Critical
Publication of CA2438339C publication Critical patent/CA2438339C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2438339A 2001-02-16 2002-02-18 Use of buprenorphine for treatment of urinary incontinence Expired - Fee Related CA2438339C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10107828.5 2001-02-16
DE2001107828 DE10107828A1 (de) 2001-02-16 2001-02-16 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE20115429U DE20115429U1 (de) 2001-09-18 2001-09-18 Opioide in der Harninkontinenz
DE20115429.3 2001-09-18
DE2001162704 DE10162704A1 (de) 2001-12-19 2001-12-19 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE10162704.1 2001-12-19
PCT/EP2002/001699 WO2002066031A1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Publications (2)

Publication Number Publication Date
CA2438339A1 CA2438339A1 (en) 2002-08-29
CA2438339C true CA2438339C (en) 2010-12-14

Family

ID=27214302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2438339A Expired - Fee Related CA2438339C (en) 2001-02-16 2002-02-18 Use of buprenorphine for treatment of urinary incontinence

Country Status (14)

Country Link
US (1) US20040102468A1 (https=)
EP (1) EP1368023B1 (https=)
JP (1) JP4908726B2 (https=)
AT (1) ATE314066T1 (https=)
AU (1) AU2002242705B2 (https=)
CA (1) CA2438339C (https=)
DE (1) DE50205438D1 (https=)
DK (1) DK1368023T3 (https=)
ES (1) ES2255607T3 (https=)
HU (1) HU229354B1 (https=)
MX (1) MXPA03006742A (https=)
NZ (1) NZ528064A (https=)
PL (1) PL204638B1 (https=)
WO (1) WO2002066031A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323421A1 (en) * 2001-12-20 2003-07-02 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
US8260389B2 (en) * 2003-10-15 2012-09-04 Hegln (Dalian) Pharmaceuticals, Inc. Bladder function monitoring methods, apparatuses, media and signals
EP1682002A4 (en) 2003-10-15 2010-03-31 Univ British Columbia METHOD AND DEVICE FOR URODYNAMIC ANALYSIS
JP6370802B2 (ja) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
EP3067357A1 (en) 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
CN107320770A (zh) * 2017-07-12 2017-11-07 江苏西宏生物医药有限公司 一种注射植入剂
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
DE69631525T2 (de) * 1995-03-03 2004-12-16 Endo Pharmaceuticals Inc. Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina

Also Published As

Publication number Publication date
JP2004525900A (ja) 2004-08-26
EP1368023A1 (de) 2003-12-10
HU229354B1 (en) 2013-11-28
MXPA03006742A (es) 2003-10-24
DE50205438D1 (de) 2006-02-02
DK1368023T3 (da) 2006-02-13
NZ528064A (en) 2006-03-31
PL204638B1 (pl) 2010-01-29
ATE314066T1 (de) 2006-01-15
US20040102468A1 (en) 2004-05-27
WO2002066031A1 (de) 2002-08-29
HUP0302984A3 (en) 2006-02-28
CA2438339A1 (en) 2002-08-29
JP4908726B2 (ja) 2012-04-04
EP1368023B1 (de) 2005-12-28
AU2002242705B2 (en) 2006-08-24
PL367401A1 (en) 2005-02-21
ES2255607T3 (es) 2006-07-01
HUP0302984A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
KR20040044953A (ko) 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물
CA2438339C (en) Use of buprenorphine for treatment of urinary incontinence
WO2013170967A1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US6841575B2 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence
AU2002220736B2 (en) Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence
WO2005107467A2 (en) Compositions including opioids and methods of their use in treating pain
RU2280444C2 (ru) Применение 6-диметиламинометил-1-фенилциклогексановых соединений для терапии недержания мочи
EP2849747B1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
US7361690B2 (en) Compositions and methods for the treatment of urinary incontinence
JP2004525900A5 (https=)
WO2013170969A1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol
US6635237B2 (en) Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence
DE10107828A1 (de) Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE10162704A1 (de) Verwendung von Buprenorphin zur Therapie der Harninkontinenz
US20050137194A1 (en) Combination of selected opioids with other active compounds for treatment of urinary incontinence
HK1204938B (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
DE20115429U1 (de) Opioide in der Harninkontinenz

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170220